NYSE - Delayed Quote USD

AbbVie Inc. (ABBV)

167.80

-1.74

(-1.03%)

At close: April 24 at 4:00 PM EDT

167.75

-0.05

(-0.03%)

Pre-Market: 7:24 AM EDT

Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?

While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.

Zacks 19 hours ago

PFE
-0.19%
LLY
-1.81%
AMGN
-0.19%
4 Large Drug Stocks to Hold on to Amid Industry Challenges

Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.

Zacks 21 hours ago

ABBV
-1.03%
LLY
-1.81%
NVO
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?

Let's look at five biotech/drug companies, MRK, SNY, BMY, GILD and ABBV, slated to release their first quarter 2024 earnings results this week.

Zacks 22 hours ago

ABBV
-1.03%
SNY

CELG-RT
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

Zacks yesterday

ABBV
-1.03%
Nvidia will soar 21% to $1,000 as its new AI chip slams would-be rivals, Morgan Stanley says. It’s among 10 stocks set to surge

“We believe earnings growth is set for a healthier runway through 2024,” Morgan Stanley’s analysts wrote.

Fortune yesterday

NVDA

ABBV
-1.03%
SBAC
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth

Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks yesterday

LLY
-1.81%
ABBV
-1.03%
Gear Up for AbbVie (ABBV) Q1 Earnings: Wall Street Estimates for Key Metrics

Get a deeper insight into the potential performance of AbbVie (ABBV) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Zacks yesterday

ABBV
-1.03%
Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is offering consumers an opportunity to be featured in upcoming campaigns for their biggest brands, including BOTOX® Cosmetic, the JUVÉDERM® Collection of Fillers, and Allē, the Allergan Aesthetics loyalty rewards program. Beginning today, consumers—including existing patients and those who are considering aesthetic treatment—can apply for a chance to be included in future brand campaigns. The first Allergan Aesthetics open casting call for BO

PR Newswire yesterday

ABBV
-1.03%
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?

Investor focus is likely to be on the sales of AbbVie's (ABBV) blockbuster immunology drugs Rinvoq and Skyrizi when it reports first-quarter results.

Zacks 2 days ago

ABBV
-1.03%
Buying the Dip in These 3 Undervalued Dividend Stocks

All three of these stocks look intriguing.

Motley Fool 2 days ago

ABBV
-1.03%
The Bad News Heading Into AbbVie's First-Quarter Earnings Report

AbbVie stock has slumped 9% off its record high in March and is facing increasingly steep competition for its biggest moneymaker, Humira.

Investor's Business Daily 5 days ago

ABBV
-1.03%
Earnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 5 days ago

ABBV
-1.03%
Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data

J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.

Zacks 5 days ago

ABBV
-1.03%
LLY
-1.81%
ROG.SW
Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study

On Thursday, Cerevel Therapeutics Holdings Inc. (NASDAQ:CERE) released topline results from its pivotal Phase 3 TEMPO-3 trial for tavapadon in Parkinson’s disease. The TEMPO-3 trial evaluated the efficacy, safety, and tolerability of tavapadon as an adjunctive therapy to levodopa (LD) in adults. The trial met its primary endpoint – patients treated with tavapadon adjunctive to LD experienced a clinically meaningful and statistically significant increase of 1.1 hours in total “on” time without tr

Benzinga 6 days ago

ABBV
-1.03%
Heard on the Street: AbbVie’s Bet on a Neuroscience Drug Maker Just Got Better

AbbVie’s acquisition of neuroscience biotech Cerevel Therapeutics hasn’t closed yet. Notably, when AbbVie announced the $8.7 billion acquisition of Cerevel back in December, the main focus of the deal was the experimental schizophrenia drug Emraclidine, part of a new class of medications that target the muscarinic receptor. Late last year, Bristol Myers Squibb also announced its entry into the field, buying Karuna Therapeutics for $14 billion. The Food and Drug Administration is reviewing Karuna’s drug for the treatment of schizophrenia.

The Wall Street Journal 6 days ago

CERE

ABBV
-1.03%
Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis

AbbVie (NYSE: ABBV) today announced positive top-line results from SELECT-GCA, a Phase 3, multicenter, randomized, double-blind, placebo-controlled study, showing upadacitinib (RINVOQ®; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remissiona from week 12 through week 52 in adults with giant cell arteritis (GCA). In this study, 46 percent of patients receiving upadacitinib 15 mg in combination with a 26-week steroid taper regime

PR Newswire 6 days ago

ABBV
-1.03%
Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study

Analysts had low expectations for Cerevel’s drug tavapadon, which was something of an afterthought in AbbVie’s proposed buyout of the biotech.

BioPharma Dive 7 days ago

ABBV
-1.03%
AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know

AbbVie (ABBV) closed at $164.25 in the latest trading session, marking a +1.05% move from the prior day.

Zacks 7 days ago

ABBV
-1.03%
Steady Income, Steady Growth: 7 Blue-Chip Dividend Stocks to Buy Now

Blue-chip dividend stocks have always been relevant. While they’re not the most exciting investments, they provide a steady hand during market uncertainty. This attribute has just become even more critical. With an already tense situation in the geopolitical realm boiling over, investors will likely seek reassurances. It doesn’t get much better than established stalwarts that pay consistent and/or reliable passive income. On this note, below are top blue-chip dividend stocks to consider. RTX (RT

InvestorPlace 8 days ago

LMT

NEE

RTX
UPDATE 1-US FDA warns of harmful reactions to fake Botox injections

The U.S. Food and Drug Administration on Tuesday alerted health care professionals and consumers that unsafe counterfeit versions of AbbVie's Botox were given to consumers for cosmetic purposes in multiple states. The U.S. Centers for Disease Control and Prevention (CDC) and the FDA are investigating reports of harmful reactions among people who received injections of counterfeit Botox. As of April 12, a total of 19 people from nine states had reported harmful reactions after receiving Botox injections from unlicensed or untrained individuals, or in non-healthcare settings, such as homes and spas, according to the CDC.

Reuters 8 days ago

ABBV
-1.03%

Performance Overview

Return	ABBV	S&P 500
YTD	+10.33%	+6.33%
1-Year	+7.51%	+22.70%
3-Year	+69.82%	+21.33%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

AbbVie Inc. (ABBV)

Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?

4 Large Drug Stocks to Hold on to Amid Industry Challenges

What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Nvidia will soar 21% to $1,000 as its new AI chip slams would-be rivals, Morgan Stanley says. It’s among 10 stocks set to surge

Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth

Gear Up for AbbVie (ABBV) Q1 Earnings: Wall Street Estimates for Key Metrics

Allergan Aesthetics Invites Consumers to Be the Face of BOTOX® Cosmetic (onabotulinumtoxinA) and Their Other Biggest Brands

AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?

Buying the Dip in These 3 Undervalued Dividend Stocks

The Bad News Heading Into AbbVie's First-Quarter Earnings Report

Earnings Preview: AbbVie (ABBV) Q1 Earnings Expected to Decline

Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data

Soon To Be Acquired Cerevel Therapeutics Reveals High Level Data From Late-Stage Parkinson's Disease Study

Heard on the Street: AbbVie’s Bet on a Neuroscience Drug Maker Just Got Better

Phase 3 SELECT-GCA Study of Upadacitinib (RINVOQ®) Showed Positive Results in Patients With Giant Cell Arteritis

Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study

AbbVie (ABBV) Increases Despite Market Slip: Here's What You Need to Know

Steady Income, Steady Growth: 7 Blue-Chip Dividend Stocks to Buy Now

UPDATE 1-US FDA warns of harmful reactions to fake Botox injections

Performance Overview